New vaccine-like shot aims to keep HER2 breast cancer from returning
Disease control
Recruiting now
This study tests an experimental immunotherapy called GLSI-100 in people with HER2-positive breast cancer who have a high risk of the cancer returning after standard treatment. The treatment is given as a series of shots over a year and aims to train the immune system to attack a…
Phase: PHASE3 • Sponsor: Greenwich LifeSciences, Inc. • Aim: Disease control
Last updated May 25, 2026 16:45 UTC